Biofilm Formation Status in ESBL-Producing Bacteria Recovered from Clinical Specimens of Patients: A Systematic Review and Meta-Analysis.

Q3 Pharmacology, Toxicology and Pharmaceutics

Infectious disorders drug targets Pub Date : 2023-01-01 DOI:10.2174/1871526522666220920141631

Masoud Keikha, Mohsen Karbalaei

{"title":"Biofilm Formation Status in ESBL-Producing Bacteria Recovered from Clinical Specimens of Patients: A Systematic Review and Meta-Analysis.","authors":"Masoud Keikha, Mohsen Karbalaei","doi":"10.2174/1871526522666220920141631","DOIUrl":null,"url":null,"abstract":"Background: Recently, the emergence and spread of extended-spectrum beta-lactamase (ESBL) bacteria have become a global health concern. In addition, the ability to form biofilm due to less impermeability to antibiotics and the horizontal transformation (conjugation) of genes involved in antibiotic resistance have exacerbated the concerns. With a comprehensive meta-analysis, this study evaluated the potential relationship between ESBL and biofilm formation.Methods: A literature search was performed using global databases, such as PubMed and Scopus, up to November 2021. We retrieved all relevant documents and selected eligible articles based on inclusion criteria. Finally, the potential association between the biofilm formation capacity and resistance of ESBL-producing bacteria was measured with an odds ratio and a 95% confidence interval.Results: In the present study, 17 articles, including 2,069 Gram-negative isolates, were considered as eligible. The prevalence of biofilm formation in all clinical isolates of ESBL and non-ESBL pathogens was 72.4% (95% CI: 60.7-81.6) and 40.5% (95% CI: 30.2-51.8), respectively. Our results showed a positive relationship between the ability for biofilm formation and conferring antibiotic resistance in ESBL-producing bacteria (OR: 3.35; 95% CI: 1.67-6.74; p-value: 0.001).Conclusion: In general, we showed the rate of biofilm formation to be significantly higher in ESBLproducing strains. Given the current results, the updated therapeutic guidelines should consider the role of biofilm production for optimal therapy, treatment course, and clinical outcomes rather than the recommendation of antimicrobial agents by focusing on the results of the antibiotic susceptibility test.","PeriodicalId":13678,"journal":{"name":"Infectious disorders drug targets","volume":"23 2","pages":"e200922208987"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infectious disorders drug targets","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1871526522666220920141631","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Recently, the emergence and spread of extended-spectrum beta-lactamase (ESBL) bacteria have become a global health concern. In addition, the ability to form biofilm due to less impermeability to antibiotics and the horizontal transformation (conjugation) of genes involved in antibiotic resistance have exacerbated the concerns. With a comprehensive meta-analysis, this study evaluated the potential relationship between ESBL and biofilm formation.

Methods: A literature search was performed using global databases, such as PubMed and Scopus, up to November 2021. We retrieved all relevant documents and selected eligible articles based on inclusion criteria. Finally, the potential association between the biofilm formation capacity and resistance of ESBL-producing bacteria was measured with an odds ratio and a 95% confidence interval.

Results: In the present study, 17 articles, including 2,069 Gram-negative isolates, were considered as eligible. The prevalence of biofilm formation in all clinical isolates of ESBL and non-ESBL pathogens was 72.4% (95% CI: 60.7-81.6) and 40.5% (95% CI: 30.2-51.8), respectively. Our results showed a positive relationship between the ability for biofilm formation and conferring antibiotic resistance in ESBL-producing bacteria (OR: 3.35; 95% CI: 1.67-6.74; p-value: 0.001).

Conclusion: In general, we showed the rate of biofilm formation to be significantly higher in ESBLproducing strains. Given the current results, the updated therapeutic guidelines should consider the role of biofilm production for optimal therapy, treatment course, and clinical outcomes rather than the recommendation of antimicrobial agents by focusing on the results of the antibiotic susceptibility test.

查看原文本刊更多论文

从患者临床标本中回收的产esbl细菌的生物膜形成状况:系统回顾和荟萃分析。

背景:近年来，广谱β -内酰胺酶(ESBL)细菌的出现和传播已成为全球关注的健康问题。此外，由于对抗生素的不渗透性较低而形成生物膜的能力以及参与抗生素耐药性的基因的水平转化(偶联)加剧了人们的担忧。通过综合meta分析，本研究评估了ESBL与生物膜形成之间的潜在关系。方法:使用PubMed、Scopus等全球数据库进行文献检索，检索时间截止到2021年11月。我们检索了所有相关文献，并根据纳入标准选择了符合条件的文章。最后，以比值比和95%置信区间测量产esbl细菌的生物膜形成能力与耐药性之间的潜在关联。结果:在本研究中，17篇文章，包括2069株革兰氏阴性分离株，被认为是合格的。所有临床分离的ESBL和非ESBL病原体中生物膜形成的发生率分别为72.4% (95% CI: 60.7-81.6)和40.5% (95% CI: 30.2-51.8)。我们的研究结果表明，在产生esbl的细菌中，生物膜形成能力与赋予抗生素耐药性之间存在正相关关系(OR: 3.35;95% ci: 1.67-6.74;假定值:0.001)。结论:总的来说，我们发现产esbls菌株的生物膜形成率明显更高。鉴于目前的结果，更新的治疗指南应考虑生物膜生产在最佳治疗、疗程和临床结果中的作用，而不是通过关注抗生素敏感性试验的结果来推荐抗菌药物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Infectious disorders drug targets Pharmacology, Toxicology and Pharmaceutics-Pharmacology

CiteScore

3.10

自引率

0.00%

发文量

123

期刊介绍： Infectious Disorders - Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular targets involved in infectious disorders e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics on drug targets involved in infectious disorders. As the discovery, identification, characterization and validation of novel human drug targets for anti-infective drug discovery continues to grow, this journal will be essential reading for all pharmaceutical scientists involved in drug discovery and development.